Following applications made by PSNC to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), a further 28 new products entered the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 August 2022:
Amantadine 50mg/5ml oral solution sugar free
Amiloride 5mg / Bumetanide 1mg tablets
Cabergoline 1mg tablets
Cabergoline 2mg tablets
Chloral hydrate 500mg/5ml oral solution
Doxepin 10mg capsules
Efmody 10mg modified-release capsules
Efmody 5mg modified-release capsules
Ephedrine hydrochloride 15mg tablets
Ephedrine hydrochloride 30mg tablets
Hydrocortisone 0.5% ointment
Liothyronine 10microgram capsules
Liothyronine 20microgram capsules
Liothyronine 5microgram capsules
Naproxen 125mg/5ml oral suspension sugar free
Ontozry 100mg tablets
Ontozry 12.5mg/25mg tablets treatment initiation pack
Ontozry 150mg tablets
Ontozry 200mg tablets
Ontozry 50mg tablets
Potassium dihydrogen phosphate 13.6% (potassium 10mmol/10ml) solution for infusion 10ml ampoules
Prednsiolone sodium phosphate 5mg suppositories
Procyclidine 10mg/2ml solution for injection ampoules
Rupatadine 10mg tablets
Tamoxifen 40mg tablets
Vazkepa 998mg capsules
For a list of all the monthly changes to the DND status of products please see the following page Notice of changes to discount not deducted (DND) status of products. A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the ‘Group Items’ heading are not listed again individually in Part II. Contractors can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria (see below).
Any products that are covered by one or more of the Group items categories below are reimbursed without any discount deduction applied.
Cold Chain Storage (ALL)
Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
Cytotoxic or Cytostatic item (ALL):
Insulins for injection (ALL)
Vaccines and antisera (ALL)
Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
Products that do not are covered by one or more of the Group item categories above must fulfil all three of the following criteria to qualify for entry to the DND list.
the manufacturer(s), AAH and Alliance do not offer pharmacy contractors a discount
fewer than 500,000 items per year are dispensed of the product
average net ingredient cost (NIC) per item is more than £50
PSNC will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, accordingly.
If a product is currently subject to the discount deduction scale and you believe that it should be added to DND list based on the criteria specified above, please contact the PSNC Dispensing and Supply Team by emailing firstname.lastname@example.org who will investigate whether the product meets the relevant DND criteria and make an application to the DHSC and NHSBSA, as appropriate.
For further information on how discount deduction works, click here.
The post 28 products added to the Discount Not Deducted (DND) list from August 2022 appeared first on PSNC Website.